Our esteemed BOD member Kevin Buchi's Tetralogic, of which he is CEO and President of the BOD has been on a nosedive for months. Last Wed/Thurs it dropped 70% in one day. There is no reason he should sit on our board. Their main goal is HBV and I don't see how he provides any value to BLT and it's aspirations for the HBV space.
$6.25 to .28====just another case of creating shareholder value. Note that TLOG was a KSS buy.
BLT Price at posting:
29.5¢ Sentiment: None Disclosure: Held